NaPro Announces Additions to Scientific Advisory Board
13 January 2004 - 12:30AM
PR Newswire (US)
NaPro Announces Additions to Scientific Advisory Board BOULDER,
Colo., Jan. 12 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics,
Inc. today announced the following new appointments to its
Scientific Advisory Board: Paul A Bunn, Jr., M.D.: Dr. Bunn is
currently the Director of the University of Colorado Cancer Center,
past president (2002-2003) of the American Society of Clinical
Oncology (ASCO), and former chairman of the Oncology Drugs Advisory
Committee (ODAC). Dr. Bunn is an authority in the field of clinical
oncology with a research specialty in lung cancer. Dr. Bunn
received his M.D. from Cornell University Medical Center. Theodore
Friedmann, M.D.: Dr. Friedmann is a Professor of Pediatrics and
Director of the Gene Therapy Program at the University of
California, San Diego. Since 2000, he has served as the Chairman of
the Recombinant DNA Advisory Committee (RAC) at the National
Institutes of Health. Dr. Friedmann has over 40 years of research
experience in the areas of genetics and molecular therapies. He
received his M.D. from the University of Pennsylvania. Susan J.
Gross, M.D.: Dr. Gross is the Co-Director of the Division of
Reproductive Genetics at Montefiore Medical Center and Albert
Einstein College of Medicine and an associate professor in
Obstetrics, Gynecology and Pediatrics. Dr. Gross performs research
and provides genetic counseling for women with hereditary cancer
and those at high risk for genetic birth defects. She is board
certified in obstetrics and gynecology and medical genetics. Dr.
Gross received her M.D. from the University of Toronto. Stephen S.
Morse, Ph.D.: Dr. Morse is Director of the Center for Public Health
and Associate Professor of Clinical Epidemiology at Columbia
University's Mailman School of Public Health. He is an expert in
the epidemiology of emerging infections, international cooperation
for infectious disease surveillance, and defense against
bioterrorism. Dr. Morse spent four years in government service as
Program Manager at the Defense Advanced Research Projects Agency
(DARPA), Department of Defense, where he co-directed the Pathogen
Countermeasures program and subsequently directed the Advanced
Diagnostics program there. He holds a Ph.D. in Virology from the
University of Wisconsin. "We are pleased to welcome these eminent
scientists to our Scientific Advisory Board," stated Robert E.
Pollack, Ph.D., Chairman of the NaPro Scientific Advisory Board.
"These distinguished experts will expand the Board's collective
expertise in NaPro's core research and development areas and help
us guide the Company's strategy to bring forward promising new
therapies in the field of oncology and the treatment of hereditary
disease." Other members of NaPro's Scientific Advisory Board are:
Robert E Pollack, Ph.D. (Chairman) Professor of Biological Sciences
& Director, Center for the Study of Science and Religion,
Columbia University Anthony J. Lechich, M.D., Senior Vice President
of Medical Affairs and Medical Director, Terence Cardinal Cooke
Health Care Center Malcolm A. S. Moore, D. Phil., Enid A Haupt
Professor of Cell Biology & Head, James Ewing Laboratory of
Developmental Hematopoiesis, Memorial Sloan-Kettering Cancer Center
Seth A. Rudnick, M.D., Managing Partner, Canaan Partners LLP Ethan
Signer, Ph.D., Executive Director, High Q Foundation, Professor of
Biology Emeritus, Massachusetts Institute of Technology Nancy S.
Wexler, Ph.D., Higgins Professor of Neuropsychology, Columbia
University About NaPro BioTherapeutics NaPro BioTherapeutics, Inc.
is a life science company focused on the development of therapies
for the targeted treatment of cancer and hereditary disease. For
more information about NaPro and its technologies, visit NaPro's
web site at http://www.naprobio.com/ . Forward Looking Statements
The statements in this news release that are not historical facts
are forward-looking statements that represent management's beliefs
and assumptions as of the date of this news release, based on
currently available information. Forward-looking statements can be
identified by the use of words such as "believes," "intends,"
"estimates," "may," "will," "should," "anticipated," "expected" or
comparable terminology or by discussions of strategy. Although the
Company believes that the expectations reflected in such
forward-looking statements are reasonable, it cannot assure that
these expectations will prove to be correct. Such statements
involve risks and uncertainties including: risks associated with
development of therapies in the field of oncology and the treatment
of hereditary disease, and all of those factors identified under
the captions "Risk Factors," "Special Note Regarding Forward
Looking Statements" or "Cautionary Note Regarding Forward Looking
Statements" in the Company's documents filed from time to time with
the SEC, including the Company's registration statement on Form
S-3, as amended, dated August 8, 2003, its Annual Report on Forms
10-K and 10-K/A for the year ending December 31, 2002 filed with
the SEC on March 27, April 30, August 8 and October 24, 2003, and
its Quarterly Report on Form 10-Q for the quarter ended October 1,
2003 filed with the Securities and Exchange Commission on November
14, 2003. Should one or more of these risks materialize (or the
consequences of such a development worsen), or should the
underlying assumptions prove incorrect, actual results could differ
materially from those forecasted or expected. The Company disclaims
any intention or obligation to update publicly or revise such
statements whether as a result of new information, future events or
otherwise. For further information, please contact L. Robert Cohen,
Vice President, Investor Relations of NaPro BioTherapeutics, Inc.,
+1-212-218-8715. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT:
L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., +1-212-218-8715; or investors, Lilian Stern
of Stern Investor Relations, +1-212-362-1200; or media, Peter
Steinerman, +1-516-374-3031, both for NaPro BioTherapeutics, Inc.
Web site: http://www.naprobio.com/
Copyright
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jul 2023 to Jul 2024